KOSDAQ - Delayed Quote KRW
Cellid, Co., Ltd. (299660.KQ)
3,980.00
+440.00
+(12.43%)
At close: May 2 at 3:30:25 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Yuil Kang Chang | CEO & Representative Director | -- | -- | -- |
| Kim Minsoo | In charge of Finance/IR(Management Support Office) & Director | -- | -- | -- |
| Kim Yookyung | Head of GMP Center & MD | -- | -- | -- |
Cellid, Co., Ltd.
142 dong Seoul National University
5th Floor Gwanak-ro 1 Gwanak-gu
Seoul, 08826
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
Corporate Governance
Cellid, Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available